Z01 BC 010270 (Z01) | |||
---|---|---|---|
Title | High-Throughput Genotyping for Genetic Epidemiology | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Smith, Michael | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $215,486 | Project Dates | 10/01/1996 - N/A |
Fiscal Year | 2008 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Autoimmune Diseases (10.0%) Cancer (100.0%) Digestive Diseases (20.0%) |
Central Nervous System - Not Including Brain (10.0%) Kaposi Sarcoma (50.0%) Kidney Cancer (10.0%) Kidney Disease (10.0%) Liver Cancer (20.0%) Lymphoma (25.0%) Non Hodgkins Lymphoma (25.0%) Prostate (10.0%) Sarcoma (50.0%) Sarcoma, Soft (Sarcoma Subset) (50.0%) |
||
Research Type | |||
Resources and Infrastructure Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
Genome-wide association analysis with a dense marker set, mapping by admixture linkage disequilibrium (MALD) with ancestry informative markers, and examination of candidate gene analysis each requires a high-throughput genotyping laboratory. Utilizing the core laboratory we have developed at the Laboratory of Genomic Diversity (LGD) has allowed determination and publication of a MALD map for disease gene discovery in African Americans. Our collaborators have now used that map and the MALD method for gene identification in prostate cancer and IL-6 levels along with gene localization in multiple sclerosis. Ongoing efforts in our laboratory are applying the MALD technology to HIV/AIDS, Hepatitis C virus (HCV), focal segmental glomerulosclerosis, and end-stage renal disease. The laboratory has also undertaken candidate gene analysis for HIV-1, HCV, HBV and cardiovascular disease complications of end-stage renal disease. |